What next for the treatment of Psoriasis in Europe?
Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.
Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease.
Are biosimilars the answer to the rising cost of RA treatment?
Our latest Free Thinking white paper explores why the uptake of Biosimilars has been slower than expected and asks what's next for RA?
Monoclonal-antibody (mAb) biologics have significantly improved treatment options and outcomes in rheumatoid arthritis (RA), particularly where patients do not respond to conventional disease-modifying anti-rheumatics.
The burden of disease from RA, including the cost of treatment, additional care and loss of productivity, is considerable. With disease onset peaking at 55 to 64 years, this burden will increase as populations age worldwide, aggravated by rising obesity and other characteristics of unhealthy lifestyles. Therapeutic mAbs, are helping to ease that load. As with most biologics, however, they come at a substantial cost.
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy Watch patient record data, uptake of biosimilars remains relatively muted, with marked inconsistencies across the major European markets. With Enbrel biosimilar Benepali about to launch across EU, we ask what’s next for RA?
Maximising uptake of biosimilars in an evolving market
Our client was developing biosimilars of two biologic drugs and wanted to understand the likely market potential for their assets.